Incidence and consequence of nontarget embolization following bland hepatic arterial embolization Journal Article

  


Authors: Newgard, B. J.; Getrajdman, G. I.; Erinjeri, J. P.; Covey, A. M.; Brody, L. A.; Sofocleous, C. T.; Brown, K. T.
Article Title: Incidence and consequence of nontarget embolization following bland hepatic arterial embolization
Abstract: Purpose: Estimate the incidence of nontarget embolization (NTE) as identified on immediate post-hepatic artery embolization CT. Materials and Methods: Two hundred hepatic embolizations performed with particles alone (bland embolization) in 147 patients between August 16, 2013 and August 26, 2014 with immediate post-procedure CT were retrospectively reviewed. Arterial anatomy, vessels treated, imaging findings of NTE, patient demographics, length of hospital stay following embolization, and procedure-related complications were recorded. The data were analyzed using two-sided t-tests and chi-squared tests. Results: Evidence of NTE was seen on post-procedure CT in 64 of 200 cases (64/200, 32%). Six organs were affected, with 69 discrete sites in 64 patients. The majority (49/69, 71.0%) involved the gallbladder. The mean length of hospital stay (LOS) for patients with and without NTE was 2.9 ± 1.5 nights (range 1–7) and 2.9 ± 2.3 nights (range 0–21), respectively (P = 0.81). NTE was more common following embolization of replaced or accessory hepatic vessels. There were three complications in the NTE group (3/64, 4.7%) following the embolization procedure, one of which was cholecystitis directly related to NTE. The other two were one incidence each of contrast-induced nephropathy and pneumonia. In the group without NTE, seven complications occurred (7/136, 5.1%, P = 0.889), including one death resulting from hepatic failure, two gastrointestinal bleeds, two hepatic abscesses, flash pulmonary edema, and pancreatitis. Conclusion: Unanticipated NTE is not uncommon after bland hepatic artery embolization, particularly after treating accessory or replaced vessels, but does not increase complications or LOS. Level of Evidence: Level 2b, Retrospective Cohort. © 2019, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Keywords: embolization; complication; hepatic malignancy
Journal Title: CardioVascular and Interventional Radiology
Volume: 42
Issue: 8
ISSN: 0174-1551
Publisher: Springer  
Date Published: 2019-08-01
Start Page: 1135
End Page: 1141
Language: English
DOI: 10.1007/s00270-019-02229-2
PUBMED: 31073823
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065648485&doi=10.1007%2fs00270-019-02229-2&partnerID=40&md5=3defd4371c754c37dd71244d07fc74cc
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. George I Getrajdman
    118 Getrajdman
  2. Anne Covey
    165 Covey
  3. Lynn Brody
    119 Brody
  4. Karen T Brown
    178 Brown
  5. Joseph Patrick Erinjeri
    200 Erinjeri
  6. Constantinos T Sofocleous
    244 Sofocleous
Related MSK Work